- Home
- SNDX vs IDT Comparison
SNDX vs IDT Comparison
Compare SNDX & IDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- IDT
- Stock Information
- Founded
- SNDX 2005
- IDT 1990
- Country
- SNDX United States
- IDT United States
- Employees
- SNDX N/A
- IDT N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- IDT Telecommunications Equipment
- Sector
- SNDX Health Care
- IDT Telecommunications
- Exchange
- SNDX Nasdaq
- IDT Nasdaq
- Market Cap
- SNDX 1.3B
- IDT 1.4B
- IPO Year
- SNDX 2016
- IDT 1996
- Fundamental
- Price
- SNDX $13.51
- IDT $50.81
- Analyst Decision
- SNDX Strong Buy
- IDT
- Analyst Count
- SNDX 11
- IDT 0
- Target Price
- SNDX $38.55
- IDT N/A
- AVG Volume (30 Days)
- SNDX 3.3M
- IDT 233.0K
- Earning Date
- SNDX 11-03-2025
- IDT 12-03-2025
- Dividend Yield
- SNDX N/A
- IDT 0.47%
- EPS Growth
- SNDX N/A
- IDT 18.50
- EPS
- SNDX N/A
- IDT 3.01
- Revenue
- SNDX $77,933,000.00
- IDT $1,231,495,000.00
- Revenue This Year
- SNDX $629.90
- IDT $0.77
- Revenue Next Year
- SNDX $114.74
- IDT N/A
- P/E Ratio
- SNDX N/A
- IDT $16.88
- Revenue Growth
- SNDX 2126.66
- IDT 2.13
- 52 Week Low
- SNDX $8.58
- IDT $44.77
- 52 Week High
- SNDX $22.50
- IDT $71.12
- Technical
- Relative Strength Index (RSI)
- SNDX 36.63
- IDT 42.87
- Support Level
- SNDX $13.00
- IDT $45.72
- Resistance Level
- SNDX $15.79
- IDT $50.32
- Average True Range (ATR)
- SNDX 1.10
- IDT 1.03
- MACD
- SNDX -0.26
- IDT 0.84
- Stochastic Oscillator
- SNDX 13.82
- IDT 87.23
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About IDT IDT Corporation Class B
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.